FDAnews
www.fdanews.com/articles/197352-phasebio-pharmaceuticals-to-test-pulmonary-arterial-hypertension-treatment-for-covid-19
PhaseBio Pharmaceuticals logo

PhaseBio Pharmaceuticals to Test Pulmonary Arterial Hypertension Treatment for COVID-19

June 1, 2020

PhaseBio Pharmaceuticals will conduct a phase 2 trial of its investigational treatment for pulmonary arterial hypertension in COVID-19 patients.

The trial will evaluate the drug, PB1046, as a treatment for hospitalized COVID-19 patients at high risk for rapid deterioration and acute respiratory distress syndrome. It will enroll approximately 210 patients at 20 sites across the U.S.

The FDA had previously granted PB1046 an orphan drug designation for treatment of pulmonary arterial hypertension and cardiomyopathy.

View today's stories